RBL Gains Strategic Investment for Medtech Startup Scale

RBL LLC has secured an investment from Modi Ventures to help launch and scale breakthrough startups into clinical-stage companies. Consequently, RBL has appointed Modi Ventures Founder/General Partner Sahir Ali to its Board of Directors.

Modi Ventures is Houston-based venture capital firm investing in biology and technology. Ali’s experience as an accomplished technology and healthcare leader, investor, and adviser will be instrumental in bridging the gap between academic biotech discoveries and the clinical care market, according to RBL.

“This investment by Modi Ventures will be instrumental to RBL’s growth as it reinforces confidence in our venture creation model and accelerates our ability to develop successful biotech startups,” RBL Managing Partner Paul Wotton stated. “Sahir’s addition to the board will also amplify this collaboration with Modi. His strategic counsel and deep understanding of field-defining technologies will be invaluable as we continue to grow and deliver on our mission.”

Ali joins existing board members Wotton, Paul Cherukuri, Omid Veiseh, Rima Chakrabarti, John Jaggers, Devyn Smith, and James Watson, a group of leaders with deep expertise in biotech innovation, clinical translation and venture building who together provide strategic guidance to help drive RBL’s continued growth and success.

“The bold thinking and entrepreneurial initiatives coming out of RBL represent an important cornerstone of the rapidly evolving Houston life sciences scene, and I am honored to contribute to this growth by joining this board,” Ali said. “Partnering my new role at RBL with the investment made by Modi can truly help not only build companies but also shape the future of patient care in a collaborative and more efficient way.”

Related: Rice University Starts Up Biotech Venture Creation Enterprise for Medtech

A parallel entrepreneur, scientist and innovator, Ali has led transformative work and built companies across AI, cloud computing and precision medicine. He serves on the board of directors of the Drug Information Association, a global life science membership association driving collaboration in drug, device and diagnostics development in pursuit of a healthier world.

“Modi Ventures’ investment is a strong signal of market validation for the acceleration model we’ve built into RBL,” commented Cherukuri, who also is chief innovation officer at Rice University. “It reflects growing investor confidence in RBL’s ability to turn breakthrough science into real-world therapies and in Houston’s rise as a global force in biotech innovation.”

Modi Ventures employs a proprietary financial engineering framework grounded in modern portfolio theory and efficient frontier principles. With $134 million under management, Modi Ventures backs category-defining companies advancing artificial intelligence (AI)-driven drug discovery, diagnostics and engineered therapeutics. The firm also invests in leading funds across the biotech and technology spectrum.